Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Bristol-Myers Squibb is collaborating with the Japanese companies Nissan Chemical Industries and Teijin Pharma to develop Nissan’s NTC-801 outside Japan. Teijin already has Japanese rights. A selective inhibitor of the acetylcholine-activated potassium ion channel, NTC-801 is currently in Phase I development in Japan for treating a form of arrhythmia. BMS will pay $40 million up front and potentially make milestone payments of up to $170 million.
This article has been sent to the following recipient: